- Home
- CTRM vs GLTO Comparison
CTRM vs GLTO Comparison
Compare CTRM & GLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CTRM | GLTO |
|---|---|---|
| Founded | 2016 | 2011 |
| Country | Cyprus | Denmark |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.2M | 1.8B |
| IPO Year | 2017 | 2020 |
Fundamental Metrics
Financial Performance| Metric | CTRM | GLTO |
|---|---|---|
| Price | $2.10 | $28.69 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $43.67 |
| AVG Volume (30 Days) | 54.9K | ★ 322.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.84 | $2.01 |
| 52 Week High | $2.67 | $38.33 |
Technical Indicators
Market Signals| Indicator | CTRM | GLTO |
|---|---|---|
| Relative Strength Index (RSI) | 43.04 | 51.77 |
| Support Level | $2.07 | $24.53 |
| Resistance Level | $2.20 | $32.86 |
| Average True Range (ATR) | 0.11 | 2.50 |
| MACD | -0.01 | -0.30 |
| Stochastic Oscillator | 17.31 | 29.94 |
Price Performance
Historical ComparisonAbout CTRM Castor Maritime Inc.
Castor Maritime Inc is a provider of seaborne transportation services for dry bulk cargo, including iron ore, coal, grain, steel products, fertilizers, cement, bauxite, sugar, and scrap metal, among others. The firm operates under three reportable segments namely (i) the dry bulk segment (ii) the containership segment and (iii) the asset management segment. It generates maximum revenue from the Dry bulk segment.
About GLTO Galecto Inc.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.